We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Second Pathology Analysis Ensures Proper Diagnosis and Treatment

By LabMedica International staff writers
Posted on 27 May 2015
A pathologic diagnosis is the foundation upon which all other treatment decisions are made with breast cancer and with the emergence of target therapy, the pathology dictates the use of potentially curable therapy.

Patients with breast disease receive appropriate care based on accurate diagnoses and accurate identification of predictive and prognostic markers as an incorrect pathologic diagnosis may lead to negative outcomes as serious as failure to treat a missed case of breast cancer or provision of unnecessary surgery, chemotherapy, and radiation.

Pathologists at the Roswell Park Cancer Institute (Buffalo, NY, USA) reviewed 502 breast core biopsy cases provided by referring institutions in a single calendar year. More...
A core needle biopsy is a procedure that removes small samples of breast tissue which are then analyzed for characteristics of breast disease. The cases in the study were defined as reflecting a minor discordance when the change in diagnosis did not impact the patient and a major discordance when patient care was impacted through a change in therapy modality.

The team found that 8% of the cases had a major discordance and 13% had a minor discordance. The most common reason for major discordance is interpreting biomarkers such the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factors type 2 (HER-2). These biomarkers can determine treatment options and may predict breast cancer survival. The second most common reason was borderline diseases. The change of diagnosis from benign to malignant or vice versa, while less common, was identified in 1% of the cases examined. This change has the most significant impact on patient care and outcome.

The scientists did not find any difference in the rate of discordance between institutions or with regard to the pathologists' seniority. However, none of the providing pathologist was specialized in breast pathology which might explain the discordance. In conclusion, they recommend that second review of the original pathologic material should be evaluated by specialized pathologist prior to any therapeutic implementations. Thaer Khoury, MD, a coauthor of the study said, “Surgical pathology is a dynamically changing specialty with frequently updated guidelines and classifications. This study underscores the need for a second review of the original pathologic material by a pathologist who specializes in breast cancer prior to implementation of breast cancer therapy.” The study was published online on April 15, 2015, in the Breast Journal.

Related Links:

Roswell Park Cancer Institute



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: Student researcher Liyan Ming, first author of the study, setting up a fluorescence imaging experiment (Photo courtesy of Riccardo Marin)

Safer, Portable and Low-Cost Imaging Solution to Revolutionize Biomedical Diagnostics

In diagnosing diseases and monitoring treatment, accurate and quick detection of temperature within biological tissues can be crucial, especially in early disease detection. Conventional methods such as... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.